US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ETF & Stock Investment

1,997.43

-24.6101-1.22%

Number of Gainers:140

Number of Losers:869

Number of Flat:21

PE:- -

High:2,027.98

Open:2,022.05

Low:1,993.25

Close:2,022.04

Volume:6.56B

Turnover:914.91B

Market Cap:93.49T

Float Cap:87.29T

Loading ...

Amazon CEO voiced concerns about Anthropic’s AI models to U.S., Reuters says

Britain expected to set out under 16s social media restrictions

Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

Incyte announces clinical data from two Phase 2 studies of INCA033989

Incyte announces results from Phase 3 frontMIND trial of tafasitamab

Eli Lilly announces new data from Phase 1 AJX-101 study

Eli Lilly announces Phase 3 BRUIN CLL-322 trial met primary endpoint

Legend Biotech announces first clinical proof-of-concept data for LB2501

Oceania Healthcare Weighs 6-Year Secured Bond Offer for NZX Listing

Ascendis Pharma completes Phase 3 PaTHway Trial

Intellia Therapeutics presents additional results from Phase 3 HAELO trial

Rhythm announces preliminary data from Phase 2 trial of setmelanotide

Mirum, Incyte report pivotal Phase 2 PROGRESS data showing zilurgisertib cuts new FOP bone lesion volume 99.9% at Week 24

Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results From Progress Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS

Crinetics says Phase 2 trial shows atumelnant cuts CAH androgen levels 67% while enabling glucocorticoid dose reduction

Belite Bio completes rolling submission of NDA to U.S. FDA for tinlarebant

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

‘It Makes Little Sense,’ Says Investor About Micron Stock

How Investors Are Reacting To China Medical System (SEHK:867) Advancing Its siRNA-Based Obesity Pipeline

Simply Wall St.

Does Cathay Pacific (SEHK:293) CFO Succession Hint At A Shift In Financial Strategy Priorities?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4585/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4585","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4585\",,,,,undefined,":{"symbol":"BK4585","market":"US","secType":"PLATE","nameCN":"ETF & Stock Investment","latestPrice":1997.4258,"timestamp":1781726399999,"preClose":2022.0359,"halted":0,"volume":6555067431,"delay":0,"changeRate":-0.012171,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-24.610107,"latestTime":"06-17 16:00:00 EDT","open":2022.0519,"high":2027.9795,"low":1993.2485,"amount":914908626220.6248,"amplitude":0.017176,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781769600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.397768,"peRate":28.605718,"turnoverRate":0.011105,"increases":141,"decrements":867,"flats":10,"marketCap":93489119821464,"floatMarketCap":87291904673080},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4585\",,,,,undefined,":{"symbol":"BK4585","high":2027.9795,"amplitude":0.017176,"preClose":2022.0359,"low":1993.2485,"pbRate":"5.397768","latestPrice":1997.4258,"volume":6555067431,"delay":0,"open":2022.0519,"prevYearClose":1827.5802,"prevWeekClose":2000.0167,"prevMonthClose":2036.7021,"prevQuarterClose":1754.6617,"fiveDayClose":1956.2634,"twentyDayClose":1977.6527,"sixtyDayClose":1766.7643,"secType":"PLATE","market":"US","turnoverRate":0.011105,"peRate":28.605718,"marketCap":93489119821464,"floatMarketCap":87291904673080,"timestamp":1781726399999,"nameCN":"ETF & Stock Investment"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4585\",,,,undefined,":{"bkCode":"BK4585","up":140,"down":869,"flat":21},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4585\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643240362","title":"Amazon CEO voiced concerns about Anthropic’s AI models to U.S., Reuters says","url":"https://stock-news.laohu8.com/highlight/detail?id=2643240362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643240362?lang=en_us&edition=fundamental","pubTime":"2026-06-15 05:30","pubTimestamp":1781472607,"startTime":"0","endTime":"0","summary":"Amazon CEO Andy Jassy raised concerns this week to Trump administration officials about potential security risks in Anthropic’s advanced AI models,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amazon-ceo-voiced-concerns-about-anthropics-ai-models-to-u-s-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amazon-ceo-voiced-concerns-about-anthropics-ai-models-to-u-s-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","LU0957791311.USD","LU0157215616.USD","LU2637965513.SGD","IE00BFXG0V08.USD","LU2271345857.HKD","LU2237957811.SGD","LU2381873111.SGD","LU0354030438.USD","LU2756315664.SGD","LU0267386448.USD","LU2237438978.USD","LU0053666078.USD","LU2362541513.USD","LU2505996509.AUD","IE000ITXATA3.USD","LU0162691827.USD","LU1868837136.USD","HK0000304805.HKD","IE00BYQQ9H92.USD","IE000F7OJYX1.SGD","LU0210528500.USD","LU1880398554.USD","SGXZ31699556.SGD","LU2362541273.HKD","LU2750360641.GBP","LU1718418525.SGD","LU0096364046.USD","LU0149725797.USD","IE0003U64NQ7.SGD","LU0823434583.USD","LU0302445910.USD","LU1935042215.USD","IE000MB6IJN5.SGD","SGXZ81514606.USD","LU0011850046.USD","LU0208291251.USD","IE000BZT7R73.USD","BK4588","LU0072461881.USD","LU0943347566.SGD","LU1035775433.USD","LU1551013425.SGD","LU1548497426.USD","LU2471134796.USD","IE000SO60NU8.SGD","BK4527","GB00BDT5M118.USD","LU1119994496.HKD","IE000WAW04H5.SGD","AMZU","LU0640476718.USD","IE000YTNTUN2.SGD","IE00BQXX3F31.USD","LU0203202063.USD","LU1935043023.USD","IE00B7SZLL34.SGD","LU0708994859.HKD","LU1815333072.USD","LU0198837287.USD","IE00B5949003.HKD","IE00BJTD4N35.SGD","LU1201861165.SGD","IE00BN29S564.USD","BK4507","LU1880398471.USD","LU0127658192.USD","LU0882574139.USD","BK4543","LU2023250504.SGD","IE0005OL40V9.USD","LU0320765059.SGD","LU0689472784.USD","LU0070302665.USD","LU0211328371.USD","LU2764263039.SGD","LU1720051108.HKD","IE00BJLML261.HKD","LU2463028550.USD","LU0096362180.USD","LU0345769631.USD","LU0345770993.USD","BK4559","LU2487616109.SGD","LU0130102774.USD","LU1935042488.USD","HK0000532082.HKD","LU2250418816.HKD","LU2125154778.USD","LU0154236417.USD","LU1267930730.SGD","LU2083900584.USD","LU1232071149.USD","LU2023250843.SGD","IE00BKPKM429.USD","LU0528227936.USD","LU2242649171.HKD","LU2054465674.USD","LU1814569148.SGD","LU1244550577.SGD","LU1066051225.USD","SG9999015945.SGD","BK4534","LU0211327993.USD","LU1244550494.USD","LU1037948897.HKD","HK0000914660.USD","IE00B19Z3B42.SGD","IE0004445015.USD","LU1934455277.USD","BK4535","LU2168564149.EUR","SG9999014898.SGD","LU0203201768.USD","LU0251142724.SGD","LU0965509010.AUD","LU1778281490.HKD","IE00BMPRXN33.USD","BK4548","LU1366333091.USD","LU1261432733.SGD","LU1868836591.USD","LU0175139822.USD","LU1429558221.USD","IE00BK4W5L77.USD","AMZD","SG9999000418.SGD","LU2360032135.SGD","LU1066053197.SGD","BK4561","LU0256863902.USD","LU2420271590.USD","SG9999015978.USD","IE00B1BXHZ80.USD","LU2089283258.USD","LU2592432038.USD","BK4566","IE000KEQY171.SGD","LU1868836914.USD","LU1861127337.USD","LU0097036916.USD","LU0251131958.USD","LU1316542783.SGD","LU1235294995.USD","LU0265550359.USD","LU2111349929.HKD","LU2087625088.SGD","LU0965509101.SGD","BK4524","LU0234572021.USD","LU2065170008.USD","LU2077746001.SGD","LU2211815571.USD","LU2275660780.HKD","LU2326559502.SGD","LU2552382215.SGD","BK4532","AMZP","LU1069344957.HKD","LU1974910355.USD","IE0009G5SDU7.USD","HK0000304797.USD","LU1496350502.SGD","AMZW","LU0174119429.USD","LU0314104364.USD","LU1116320901.HKD","LU2471134523.USD","LU0648000940.SGD","LU0048584097.USD","LU0345768740.USD","LU0080751232.USD","LU2552382058.USD","LU0133085943.USD","LU0056508442.USD","LU1496350171.SGD","LU2065171402.SGD","SG9999018857.SGD","IE00B775H168.HKD","LU0323591593.USD","LU2746668461.USD","LU0061474960.USD","LU2417539215.USD","LU2471134879.HKD","LU2452424414.USD","BK4538","LU1791710400.SGD","IE00B4YYXB79.USD","LU2720916845.USD","LU2602419157.SGD","LU2896262040.SGD","BK4533","LU2543165471.USD","LU2860962120.EUR","LU1066051811.HKD","LU1037948541.HKD","LU0345774391.USD","LU0672654240.SGD","SG9999014880.SGD","LU0210533765.USD","LU2403377893.USD","LU2089284900.SGD","IE00B19Z9505.USD","LU1914381329.SGD","LU2168563687.JPY","HK0000914686.HKD","BK4604","SG9999001077.SGD","BK4579","LU0070217475.USD","IE0009356076.USD","LU1989764664.SGD","BK4581","LU0353189763.USD","LU2361045086.USD","LU0289960550.SGD","LU2065169927.USD","LU0390134368.USD","AMZZ","TMSOF","LU2357305700.SGD","LU2265009873.SGD","IE00B5TLWC47.USD","LU0820561909.HKD","LU0320765489.SGD","LU0143551892.USD","LU0889565833.HKD","LU0985320562.USD","LU1720051017.SGD","BK4550","IE00B3S45H60.SGD","LU1629891620.HKD","LU1791710582.SGD","LU2430703178.SGD","IE00B775SV38.USD","LU1839511570.USD","SG9999002224.SGD","LU2462157665.USD","LU2247934214.USD","LU1127390331.HKD","BK4220","LU1267930490.SGD","LU1674673428.USD","LU2462591350.SGD","AMZY","LU2360106780.USD","LU1244550221.USD","LU1861559042.SGD","LU0861579265.USD","IE00B19Z8W00.USD","LU0158827781.USD","LU1066051498.USD","IE00BFSS7M15.SGD","LU0312595415.SGD","LU0354030511.USD","LU2462591277.SGD","LU2108987350.USD","LU0256863811.USD","IE00B19Z3581.USD","LU0109392836.USD","LU0029864427.USD","LU0345769128.USD","LU1861558580.USD","IE00BMPRXR70.SGD","LU0130103400.USD","LU2063271972.USD","LU1691799644.USD","LU2023251221.USD","AZYY","LU0072462426.USD","LU0980610538.SGD","LU0642271901.SGD","BK4596","LU0348723411.USD","LU0820561818.USD","IE0034235303.USD","LU1116320737.USD","LU0310800379.SGD","LU1267930573.SGD","LU2471134952.CNY","BK4554","LU0107464264.USD","LU0823421416.USD","AMZN","LU2168564222.USD","LU2065171311.SGD","LU0724617625.USD","SGXZ51526630.SGD","LU0128525929.USD","LU1280957306.USD","LU2764263203.CNY","LU0964807845.USD","LU0788109477.HKD","LU0310799852.SGD","LU2746668974.SGD","LU2764262908.HKD","SG9999002232.USD","LU1323610961.USD","LU0742534661.SGD","IE00BQXX3D17.EUR","IE000W1ABFV2.USD","LU0345774631.USD","IE00B19Z8X17.USD","LU2028103732.USD","LU1988902786.USD","LU0466842654.USD","LU2237957902.USD","IE00BKVL7J92.USD","LU1934455194.USD","LU1366192091.USD","LU0345768153.USD","BK4612","LU2750360997.AUD","IE00BWXC8680.SGD","LU1868836757.USD","IE0004445239.USD","LU0823434740.USD","IE0004091025.USD","LU1803068979.SGD","LU1633808545.USD","USAW.SI","LU0079474960.USD","LU2954938101.SGD","LU2092627202.USD","LU0787776722.HKD","LU1435385759.SGD","LU0061475181.USD","LU2092937148.SGD","LU2168564065.EUR","IE00BJJMRY28.SGD","LU0234570918.USD","LU2361044865.SGD","IE00BMPRXQ63.HKD","IE00B4JS1V06.HKD","SG9999015986.USD","LU0719512351.SGD","LU2236285917.USD","BK4503","LU0276348264.USD","IE00BJJMRX11.SGD","LU0215105999.USD","LU1917777945.USD","LU2242650005.HKD","IE00BQXX3C00.GBP","LU0683600562.USD","SG9999004303.SGD","LU2125154935.USD","LU1935043536.SGD","LU2361044949.HKD","LU0210536198.USD","BK4122","SGXZ23171101.USD","LU2456880835.USD","LU0494093205.USD","LU0138981039.USD","LU0308772762.SGD","LU1153585028.USD","LU1934455863.HKD","IE00B3SWFQ91.USD","IE00BKDWB100.SGD","LU0823421333.USD","LU0342679015.USD","LU0061474705.USD","LU0965508806.USD","LU1084165304.USD","BK4551","LU2211817866.USD","IE00BK4W5M84.HKD","LU0823411888.USD","LU1852331112.SGD","LU0353189680.USD","IE0004086264.USD","SG9999014906.USD","LU2461242641.AUD","LU2999663052.SGD","LU0170899867.USD","LU1804176565.USD","LU2430703251.USD","SG9999014914.USD","LU0316494557.USD","LU0820562030.AUD","LU1883839398.USD","LU2430703095.HKD","SG9999015952.SGD","LU0289941410.SGD","LU2756315318.SGD","LU2168564495.EUR","IE00B1XK9C88.USD","BK4585","LU0238689110.USD","LU0417517546.SGD","LU0708995401.HKD","LU1823568750.SGD","LU2362540622.SGD","LU0456855351.SGD","LU1201861249.SGD","LU2552382132.HKD","LU1674673691.USD","LU0048573561.USD","IE00BFSS8Q28.SGD","LU0265550946.USD","BK4592","LU2264538146.SGD","LU0077335932.USD","LU2087621335.USD","LU2023250330.USD","LU1989764748.USD","IE00B7KXQ091.USD","LU0965509283.SGD","LU0786609619.USD","LU0345770308.USD","LU1046421795.USD","LU1868837300.USD","IE0000B7K699.USD","LU2505996681.GBP","LU1074936037.SGD","LU0109391861.USD","LU2097829019.USD","LU1064131342.USD","LU0648001328.SGD","LU1935042991.SGD","BK4598","SG9999017495.SGD","LU1145028129.USD","LU1551013342.USD","LU2106854487.HKD","SG9999018865.SGD","IE0002270589.USD","LU2317271919.USD","IE00BJTD4V19.USD","IE0001KFT4U8.USD","LU2213496289.HKD","SGXZ99366536.SGD","LU0082616367.USD","LU0158827948.USD","LU0251132253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643864240","title":"Britain expected to set out under 16s social media restrictions","url":"https://stock-news.laohu8.com/highlight/detail?id=2643864240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643864240?lang=en_us&edition=fundamental","pubTime":"2026-06-15 05:30","pubTimestamp":1781472600,"startTime":"0","endTime":"0","summary":"Britain expected to set out under 16s social media restrictionsAnnouncement expected on Monday morningUK has held a consultation on reducing social media harmsMinister says parents back a social media","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nL8N42M06L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","LU0128525689.USD","LU1670710588.SGD","LU2430703178.SGD","LU2552382132.HKD","LU1244550221.USD","IE0009356076.USD","LU2360106780.USD","IE0004086264.USD","LU1894683348.USD","LU2111349929.HKD","LU0648000940.SGD","BK4550","LU1496350171.SGD","IE0034235188.USD","LU1066053197.SGD","LU1823568750.SGD","LU0234572021.USD","LU1804176565.USD","IE00BBT3K403.USD","LU2746668461.USD","LU0203201768.USD","SG9999014906.USD","SG9999014542.SGD","IE000SO60NU8.SGD","LU0494093205.USD","LU1043141123.HKD","LU0174119429.USD","LU0552385451.USD","LU0234570918.USD","LU0070217475.USD","LU0061475181.USD","SG9999018865.SGD","LU1868836757.USD","IE00BN8TJ469.HKD","LU2756315664.SGD","IE0009G5SDU7.USD","IE000ITXATA3.USD","LU1951198990.SGD","LU0310799852.SGD","LU1670628061.USD","LU1430594728.SGD","LU0426417589.USD","LU2106854487.HKD","LU0314106906.USD","LU0477156953.USD","LU2720916845.USD","LU1720051017.SGD","LU2237957811.SGD","LU2023250330.USD","LU0976567544.SGD","LU0048584097.USD","LU0302445910.USD","LU0957808578.USD","LU2404859741.USD","SG9999014567.USD","LU0082616367.USD","SG9999002232.USD","IE0004445239.USD","LU2077746001.SGD","META","IE00BFMHRM44.USD","LU2097344357.USD","IE00B19Z3581.USD","BK4507","GOOY","LU1400636574.HKD","IE000YTNTUN2.SGD","LU2063271972.USD","IE000WAW04H5.SGD","GB00B4QBRK32.GBP","LU2420271590.USD","IE00B19Z8X17.USD","LU1032955483.USD","LU1803068979.SGD","LU0994945656.USD","LU1267930573.SGD","LU0175139822.USD","IE000KEQY171.SGD","LU2211815571.USD","BK4561","LU2361044865.SGD","LU0345769631.USD","GB00BDT5M118.USD","LU2322448957.HKD","SGXZ31699556.SGD","LU0130517989.USD","LU0476273544.USD","LU0889565833.HKD","LU0985320562.USD","LU2092937148.SGD","LU2491050071.SGD","LU1852331112.SGD","LU1815336760.USD","LU2746668974.SGD","IE00B5949003.HKD","LU0964807845.USD","LU0127658192.USD","SGXZ81514606.USD","LU2417539215.USD","LU0072461881.USD","LU1935042991.SGD","LU2237438978.USD","LU0079474960.USD","LU0289739343.SGD","LU0433182093.SGD","LU1880398554.USD","SG9999000418.SGD","LU2242650005.HKD","LU1145028129.USD","LU1496350502.SGD","IE00BQXX3C00.GBP","LU2087625088.SGD","LU1642822529.SGD","LU0312595415.SGD","LU0323591593.USD","IE00B775H168.HKD","LU1914381329.SGD","LU1551013425.SGD","LU0320765489.SGD","IE00BJJMRX11.SGD","LU0289961442.SGD","LU2602419157.SGD","LU2168563687.JPY","LU0417517546.SGD","LU1868836914.USD","SG9999014575.USD","BK4579","SG9999015341.SGD","IE0002270589.USD","LU2326559502.SGD","LU1066051225.USD","LU1732799900.SGD","LU2764263203.CNY","LU0128525929.USD","LU1697837992.HKD","LU0690374961.EUR","LU0107464264.USD","LU0642271901.SGD","LU1043141396.HKD","IE00BJLML261.HKD","LU0072462426.USD","LU2264538146.SGD","LU1046421795.USD","LU2362541273.HKD","LU1974910355.USD","LU1629891620.HKD","LU1267930490.SGD","LU2456880835.USD","BK4566","LU1366192091.USD","LU2764262908.HKD","LU0820561818.USD","LU0314104364.USD","IE00B7SZLL34.SGD","LU1116320737.USD","LU0124676726.USD","LU0211326755.USD","LU1917777945.USD","LU1489326972.SGD","LU2028103732.USD","LU1059921491.USD","LU1670710661.SGD","LU0158827948.USD","LU0878866978.SGD","LU0823421416.USD","BK4576","BK4543","LU0211327993.USD","LU1564329461.SGD","SG9999014880.SGD","IE0004445015.USD","LU1119994496.HKD","IE00BJTD4N35.SGD","LU0256863811.USD","LU2750360997.AUD","LU0466842654.USD","LU0784384876.USD","LU2236285917.USD","LU1674673691.USD","GGLL","IE00BZ1G4Q59.USD","SG9999018857.SGD","LU2125909247.SGD","LU1989772840.SGD","METW","LU0069063385.USD","LU0708994859.HKD","LU2065169927.USD","LU0133085943.USD","LU0276348264.USD","LU0215105999.USD","LU0154236417.USD","SG9999015945.SGD","LU0528227936.USD","LU1280957306.USD","LU2125909593.SGD","LU0477156797.USD","LU2097344431.USD","IE00BSNM7G36.USD","LU1935042215.USD","LU1803068623.USD","LU0052756011.USD","LU0985489474.SGD","LU2168564065.EUR","SG9999014898.SGD","LU1267930813.SGD","BK4612","LU2756315318.SGD","LU1674673428.USD","LU1069344957.HKD","LU1992135399.USD","LU1861558580.USD","LU0267386448.USD","LU1221951129.SGD","LU2023250504.SGD","BK4598","LU0225283273.USD","IE000BZT7R73.USD","IE00B19Z8W00.USD","LU1868837300.USD","LU2357305700.SGD","LU0130518102.USD","LU2250418816.HKD","FBYY","LU2098885051.SGD","LU2505996509.AUD","LU1894683264.USD","LU0251131958.USD","LU1153585028.USD","LU0130103400.USD","LU1564329032.USD","LU0157215616.USD","IE00BMPRXR70.SGD","IE00BKVL7J92.USD","LU0868494708.USD","LU0795875086.SGD","BK4581","LU0211326839.USD","LU0203347892.USD","LU2491050154.USD","IE00BJJMRY28.SGD","LU1585245621.USD","LU0784385840.USD","LU1261432733.SGD","LU2552382215.SGD","LU0472753341.HKD","LU1035775433.USD","LU0143551892.USD","LU2487616109.SGD","LU1121112475.USD","LU0109391861.USD","IE00B19Z9505.USD","LU0080751232.USD","IE00BN29S564.USD","IE0001KFT4U8.USD","HK0000819398.USD","LU0648001328.SGD","LU0203345920.USD","LU0553294199.USD","LU0198837287.USD","LU1989772923.USD","SG9999002224.SGD","LU1935043536.SGD","LU1699723380.USD","LU0820562030.AUD","LU0726765562.USD","SG9999001077.SGD","IE00BMPRXN33.USD","LU0170899867.USD","LU1235294995.USD","LU1323610961.USD","LU0210536198.USD","LU2592432038.USD","LU2125154778.USD","LU0210528500.USD","LU0345768153.USD","SG9999015986.USD","LU1880398471.USD","LU0048573561.USD","LU2275660780.HKD","LU1923623000.USD","BK4585","LU2237957902.USD","IE00BKPKM429.USD","LU0354030511.USD","LU1989764664.SGD","LU1720051108.HKD","SG9999015952.SGD","LU1935043023.USD","LU0310800965.SGD","LU2552382058.USD","LU1989764748.USD","LU1815333072.USD","SG9999015978.USD","LU2242649171.HKD","IE00BK4W5M84.HKD","LU2272731865.HKD","LU1400636491.USD","LU2361044949.HKD","LU0942090050.USD","LU0320765059.SGD","LU0011850046.USD","BK4524","LU2433249047.HKD","LU0316494557.USD","LU0738911758.USD","LU0557290698.USD","GOOW","LU2505996681.GBP","LU0426412945.USD","LU0208291251.USD","IE00BK4W5L77.USD","LU1670711040.USD","GB00B4LPDJ14.GBP","LU0345770308.USD","LU0511384066.AUD","BK4503","LU0823434740.USD","HK0000914660.USD","SG9999014914.USD","LU2168564222.USD","LU0949170426.SGD","LU1242518931.SGD","LU0345774391.USD","LU2097829019.USD","LU1429558221.USD","IE00BDRTCR15.USD","LU2213496289.HKD","IE0034235295.USD","LU0256863902.USD","LU1074936037.SGD","LU2065171311.SGD","LU0742534661.SGD","LU1670711123.USD","LU2089284900.SGD","LU0265550359.USD","LU2065171402.SGD","GOOP","IE00BJTD4V19.USD","LU2462591350.SGD","LU2462591277.SGD","LU1202635105.USD","LU2764263039.SGD","LU1791710400.SGD","LU1633808545.USD","LU2430703095.HKD","LU2247934214.USD","LU0203202063.USD","LU2491049909.HKD","LU0689626769.HKD","LU1548497426.USD","IE00B19Z3B42.SGD","BK4538","LU2087621335.USD","LU0077335932.USD","FBY","LU1127390331.HKD","LU1732800096.USD","LU1232071149.USD","LU2361045086.USD","IE00BD6J9T35.USD","LU2750360641.GBP","LU2244417387.USD","LU1003077747.HKD","LU2458330243.SGD","LU0672654240.SGD","LU0251142724.SGD","LU0109392836.USD","LU1645745479.HKD","IE0000B7K699.USD","IE00B3SWFQ91.USD","LU0162691827.USD","LU1670756490.USD","LU0882574139.USD","LU1718418525.SGD","LU1196500208.SGD","LU0158827781.USD","LU0444973449.USD","IE00BFSS7M15.SGD","LU2168564149.EUR","LU0053666078.USD","LU0823434583.USD","IE00BDCRKT87.USD","LU1084165304.USD","LU0943347566.SGD","LU1861559042.SGD","LU2168564495.EUR","LU2125154935.USD","LU2191332357.HKD","LU0345768740.USD","LU1564329115.USD","LU0545039389.USD","LU2065170008.USD","LU2317271919.USD","IE00BWXC8680.SGD","LU0057025933.USD","LU2954938101.SGD","LU0787776722.HKD","LU0096362180.USD","LU0979878070.USD","LU0708995401.HKD","LU1066051498.USD","LU2271345857.HKD","LU0354030438.USD","LU2272731600.USD","LU2133065610.SGD","LU1778281490.HKD","HK0000532082.HKD","SG9999014559.SGD","LU2360032135.SGD","IE000W1ABFV2.USD","LU0061474960.USD","LU2381873111.SGD","GOOGL","LU2272731782.SGD","LU1839511570.USD","SG9999017495.SGD","LU1201861249.SGD","BK4588","HK0000914686.HKD","BK4573","LU2054465674.USD","LU2430703251.USD","LU2462157665.USD","LU0823421333.USD","IE00BQXX3D17.EUR","BK4514","LU1868837136.USD","IE00B4YYXB79.USD","IE00B7KXQ091.USD","LU0187121727.USD","LU2092627202.USD","LU2089283258.USD","LU0690374615.EUR","IE00BMPRXQ63.HKD","LU0308772762.SGD","GGLS","LU0912757837.SGD","LU1242518857.USD","LU1551013342.USD","LU0211331839.USD","LU2471134879.HKD","LU1435385759.SGD","LU1244550577.SGD","LU1868836591.USD","LU0949170772.SGD","LU0149725797.USD","LU0724617625.USD","LU0342679015.USD","GOOX","LU0980610538.SGD","LU1564329628.SGD","BK4527","LU0683600562.USD","LU2102340556.USD","SG9999015358.SGD","LU2471134523.USD","LU2458330169.SGD","LU0868494617.USD","LU2265009873.SGD","LU0784383803.USD","LU0640476718.USD","LU1935042488.USD","LU2404859667.USD","LU0006306889.USD","LU2473716301.USD","LU2347655156.SGD","LU1814569148.SGD","LU0353189680.USD","IE00BQXX3F31.USD","LU2463028550.USD","LU0310800379.SGD","LU0957791311.USD","LU1201861165.SGD","LU0094547139.USD","LU0353189763.USD","LU1267930730.SGD","LU1303367103.USD","LU0792757196.USD","LU0786609619.USD","LU0795875169.SGD","LU1066051811.HKD","BK4602","LU1791710582.SGD","LU2023250843.SGD","BK4533","LU0068578508.USD","LU2023251221.USD","SG9999004303.SGD","LU0211328371.USD","IE00BLSP4452.SGD","LU2322448791.USD","LU0348723411.USD","LU1506573853.SGD","LU0210533765.USD","LU1988902786.USD","LU1221951046.USD","IE00BLSP4239.USD","LU1400636657.SGD","LU0496365809.HKD","GOU","SGXZ99366536.SGD","BK4574","IE000F7OJYX1.SGD","LU2347655073.USD","LU1267930227.SGD","LU0345769128.USD","LU1571399168.USD","LU2362541513.USD","LU2471134796.USD","LU0265550946.USD","HK0000304805.HKD","SGXZ23171101.USD","BK4592","IE00BKDWB100.SGD","LU2362540622.SGD","LU0138981039.USD","LU0788109477.HKD","LU0444971666.USD","LU0106261372.USD","LU1116320901.HKD","BK4532","LU0719512351.SGD","LU1366333091.USD","LU2860962120.EUR","IE0003U64NQ7.SGD","LU0289960550.SGD","BK4534","LU1670627923.USD","LU0029864427.USD","BK4587","METU","IE00BYXW3230.USD","IE0005OL40V9.USD","LU0689472784.USD","IE00B1XK9C88.USD","IE000MB6IJN5.SGD","LU0096364046.USD","LU1064131342.USD","IE00BHPRN162.USD","IE00BFSS8Q28.SGD","LU0345770993.USD","LU0345774631.USD","LU2461242641.AUD","LU2999663052.SGD","LU0061474705.USD","METD","LU1951200564.SGD","LU2471134952.CNY","SGXZ51526630.SGD","LU1992135472.HKD","LU2403377893.USD","BK4077","LU0661504455.SGD","LU1923622614.USD","IE0034235303.USD","LU0784385170.HKD","LU1316542783.SGD","IE00B1BXHZ80.USD","LU0251132253.USD","LU2896262040.SGD","LU0889566641.SGD","FBL","LU1244550494.USD","LU1301847155.USD","HK0000304797.USD","LU0130102774.USD","LU0097036916.USD","IE0004091025.USD","LU0070302665.USD","IE00B4JS1V06.HKD","LU0820561909.HKD","LU0056508442.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643333240","title":"Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643333240","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643333240?lang=en_us&edition=fundamental","pubTime":"2026-06-15 05:20","pubTimestamp":1781472007,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced Phase 2 results from Cohort 1 of the Progress study evaluating zilurgisertib, an investiga...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/incyte-mirum-announces-phase-2-results-from-cohort-1-of-progress-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/incyte-mirum-announces-phase-2-results-from-cohort-1-of-progress-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","BK4139","BK4550","BK4588","MIRM","PRGS","BK4097","LU2065732104.USD","INCY","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643247046","title":"Incyte announces clinical data from two Phase 2 studies of INCA033989","url":"https://stock-news.laohu8.com/highlight/detail?id=2643247046","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643247046?lang=en_us&edition=fundamental","pubTime":"2026-06-15 05:15","pubTimestamp":1781471733,"startTime":"0","endTime":"0","summary":"Incyte (INCY) announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/incyte-announces-clinical-data-from-two-phase-2-studies-of-inca033989-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/incyte-announces-clinical-data-from-two-phase-2-studies-of-inca033989-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INCY","BK4532","BK4585","BK4139","BK4550","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643028247","title":"Incyte announces results from Phase 3 frontMIND trial of tafasitamab","url":"https://stock-news.laohu8.com/highlight/detail?id=2643028247","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643028247?lang=en_us&edition=fundamental","pubTime":"2026-06-15 05:10","pubTimestamp":1781471435,"startTime":"0","endTime":"0","summary":"Incyte (INCY) announced positive results from the Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab, a humanized Fc-modifie...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/incyte-announces-results-from-phase-3-frontmind-trial-of-tafasitamab-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/incyte-announces-results-from-phase-3-frontmind-trial-of-tafasitamab-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","INCY","BK4532","BK4585","BK4550","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643470142","title":"Eli Lilly announces new data from Phase 1 AJX-101 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2643470142","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643470142?lang=en_us&edition=fundamental","pubTime":"2026-06-15 05:05","pubTimestamp":1781471135,"startTime":"0","endTime":"0","summary":"Eli Lilly (LLY) announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor demonstrated an “encourag...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eli-lilly-announces-new-data-from-phase-1-ajx-101-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eli-lilly-announces-new-data-from-phase-1-ajx-101-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1232071149.USD","LU0122379950.USD","LU0256863902.USD","LU0320765059.SGD","LU0708995401.HKD","LU2361045086.USD","LU0823434583.USD","LU2746668974.SGD","LU2237443549.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","LU2028103732.USD","LU2602419157.SGD","IE00B7KXQ091.USD","LU0133085943.USD","LU0882574139.USD","LU2361044949.HKD","IE00BN29S564.USD","LU2089984988.USD","LU2324357040.USD","LLYX","LU2089283258.USD","LU2271345857.HKD","LU1057294990.SGD","LU0203202063.USD","BK4581","LU1093756325.SGD","LU1814569148.SGD","LU2756315318.SGD","SGXZ57979304.SGD","LU2456880835.USD","LU0466842654.USD","LU2106854487.HKD","LU0882574055.USD","BK4585","LU2108987350.USD","LU2746668461.USD","BK4007","SG9999015952.SGD","LU1804176565.USD","LU2211815571.USD","LLII","LU0097036916.USD","LU0109391861.USD","LU1323610961.USD","LU2471134879.HKD","LU2360106947.USD","LU2552382215.SGD","LU2023250330.USD","LU0471298777.SGD","LU0689472784.USD","SG9999014914.USD","LU1720051017.SGD","LU2461242641.AUD","LU0672654240.SGD","GB00BDT5M118.USD","IE0004445239.USD","BK4534","IE00BJT1NW94.SGD","LU0238689110.USD","LU0353189763.USD","LU0456855351.SGD","LU1623119135.USD","LU2237443978.SGD","LU2896262040.SGD","SG9999014898.SGD","LU1868837136.USD","LU1023059063.AUD","LU2063271972.USD","IE0002141913.USD","IE00B2B36J28.USD","LU0432979614.USD","IE00BK4W5M84.HKD","LU0354030511.USD","LU2491050154.USD","LU1868836591.USD","SGXZ81514606.USD","LU0823434740.USD","SG9999018865.SGD","LU2023250504.SGD","BK4588","SGXZ51526630.SGD","LU0158827948.USD","LLY","LU2237443895.HKD","IE00BJLML261.HKD","LU1035775433.USD","LU2168564149.EUR","LU2750360641.GBP","IE00B1XK9C88.USD","IE00BJJMRZ35.SGD","LU0225283273.USD","BK4599","ELIL","IE00BFSS8Q28.SGD","LU0234572021.USD","LU2265009873.SGD","IE00BWXC8680.SGD","LU0316494557.USD","LU0079474960.USD","LU0109394709.USD","LU0353189680.USD","IE00BK4W5L77.USD","SGXZ99366536.SGD","IE0005OL40V9.USD","LU2491049909.HKD","LU1267930730.SGD","LU1093756168.USD","LU0823416689.USD","LU2552382132.HKD","LU0061475181.USD","LU0417517546.SGD","LU1064131342.USD","LU0943347566.SGD","LU0256863811.USD","LU2491050071.SGD","LU1366192091.USD","LU2471134796.USD","LU0323591593.USD","LU2213496289.HKD","LU2168564222.USD","SG9999001176.USD","LU2468319806.SGD","LU0786609619.USD","LU2112291526.USD","IE0004445015.USD","LU2087625088.SGD","LU0683600562.USD","IE00B4JS1V06.HKD","IE0001KFT4U8.USD","SG9999017495.SGD","IE00BJJMRY28.SGD","LU0006306889.USD","LU2023251221.USD","LU0820562030.AUD","LU1548497426.USD","LU2750360997.AUD","SG9999015978.USD","LU2236285917.USD","LU0640476718.USD","LU1145028129.USD","LU1720051108.HKD","LU2357305700.SGD","LU0158827781.USD","LU1061106388.HKD","LU0385154629.USD","LU0471298694.HKD","LU1629891620.HKD","SG9999018857.SGD","LU0096364046.USD","SG9999013999.USD","LU2471134952.CNY","LU0820561818.USD","LU2237438978.USD","LU1868837300.USD","IE00BFSS7M15.SGD","LU0889565916.HKD","LU2462157665.USD","LU1280957306.USD","LU0210536198.USD","LU2237443382.USD","SG9999014880.SGD","SGXZ31699556.SGD","LLYZ","LU1983299246.USD","LU1989771016.USD","SG9999015986.USD","LU0114720955.EUR","LU1868836914.USD","LU2168563687.JPY","LU2471134523.USD","LU0787776722.HKD","LU0964807845.USD","LU2756315664.SGD","LU2089284900.SGD","LU0058720904.USD","LU1712237335.SGD","LU0354030438.USD","LU2168564065.EUR","LU1551013425.SGD","LU1974910355.USD","LU2111349929.HKD","BK4533","LU0198837287.USD","LU0203201768.USD","LU1868836757.USD","LU2237443622.USD","LU1551013342.USD","LU1917777945.USD","LU2168564495.EUR","ELIS","LU2264538146.SGD","BK4516","SG9999001176.SGD","LU2237443465.HKD","LU0820561909.HKD","IE0009355771.USD","LU2552382058.USD","LU0106261372.USD","LU2417539215.USD","LU0094547139.USD","IE00BKDWB100.SGD","LU1069344957.HKD","SG9999015945.SGD","LU2361044865.SGD","LU1988902786.USD","LU0289739699.SGD","LU1291159041.SGD","LU1127390331.HKD","IE00B1BXHZ80.USD","IE00BJJMRX11.SGD","IE00BKPKM429.USD","IE00BFTCPJ56.SGD","LU0266013472.USD","IE00B775H168.HKD","SG9999014906.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643043247","title":"Eli Lilly announces Phase 3 BRUIN CLL-322 trial met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2643043247","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643043247?lang=en_us&edition=fundamental","pubTime":"2026-06-15 05:05","pubTimestamp":1781471106,"startTime":"0","endTime":"0","summary":"Eli Lilly (LLY) and Company announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jaypirca, a non-covalent Bruton tyrosine kinase inhi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eli-lilly-announces-phase-3-bruin-cll-322-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eli-lilly-announces-phase-3-bruin-cll-322-trial-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2089284900.SGD","LU0820562030.AUD","LU2106854487.HKD","LU0058720904.USD","LU2468319806.SGD","SG9999018865.SGD","LU0456855351.SGD","LU0823434583.USD","LU1720051108.HKD","IE00BK4W5L77.USD","IE00BKDWB100.SGD","LU0316494557.USD","IE00BN29S564.USD","LU1868836757.USD","LU2471134879.HKD","LU0158827948.USD","LU1974910355.USD","IE00BK4W5M84.HKD","LU0640476718.USD","LU0786609619.USD","LU2237443622.USD","LU2456880835.USD","LU2471134952.CNY","LU2896262040.SGD","IE0004445015.USD","LU1057294990.SGD","LU1548497426.USD","LU2746668974.SGD","IE0004445239.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","IE00B7KXQ091.USD","LU2023250330.USD","LU2168563687.JPY","LU2491050071.SGD","BK4588","SG9999015952.SGD","LU1232071149.USD","LU2461242641.AUD","LU1551013342.USD","IE00B775H168.HKD","LU0820561818.USD","LU0006306889.USD","LU0203201768.USD","LU1323610961.USD","LU2236285917.USD","LU1804176565.USD","LU2746668461.USD","LU1551013425.SGD","LU0203202063.USD","LU2462157665.USD","LU0672654240.SGD","IE00BJT1NW94.SGD","LU2264538146.SGD","SGXZ51526630.SGD","SGXZ57979304.SGD","LU0689472784.USD","IE00BFSS8Q28.SGD","SG9999014898.SGD","LU0466842654.USD","LU2063271972.USD","LU0823416689.USD","LU1629891620.HKD","SG9999001176.USD","LU1868837136.USD","LU2168564065.EUR","LLYX","LU0417517546.SGD","SG9999018857.SGD","LU2089984988.USD","LU1061106388.HKD","LU2111349929.HKD","LU2168564149.EUR","SG9999014914.USD","LU2271345857.HKD","LU1814569148.SGD","LU2237438978.USD","IE00B1BXHZ80.USD","IE0005OL40V9.USD","LU0225283273.USD","LU1868836914.USD","LU2213496289.HKD","LU1366192091.USD","IE00BWXC8680.SGD","BK4533","LU2112291526.USD","LU2324357040.USD","LU2108987350.USD","LU0385154629.USD","LLYZ","ELIS","SG9999001176.SGD","LU2491049909.HKD","LU0122379950.USD","LU0353189680.USD","LU1917777945.USD","LU2361044865.SGD","LU0708995401.HKD","LU1868836591.USD","LU0683600562.USD","LU1291159041.SGD","LU2417539215.USD","LU0256863811.USD","SG9999013999.USD","SG9999014906.USD","LU0133085943.USD","LU1267930730.SGD","LU1069344957.HKD","LU0823434740.USD","LU1720051017.SGD","IE00BFSS7M15.SGD","LU2552382215.SGD","LU2023251221.USD","LU0210536198.USD","LU2023250504.SGD","IE00B1XK9C88.USD","LU0889565916.HKD","LU1064131342.USD","LU1989771016.USD","ELIL","LU2361045086.USD","SG9999014880.SGD","LU2756315318.SGD","LU0353189763.USD","LU2491050154.USD","SG9999015978.USD","LU0266013472.USD","LU0471298777.SGD","LU0096364046.USD","IE00BJLML261.HKD","BK4599","LU0882574139.USD","LU2471134523.USD","LU0238689110.USD","LU2471134796.USD","LU0323591593.USD","SG9999017495.SGD","SG9999015945.SGD","LU0094547139.USD","LU2360106947.USD","SG9999015986.USD","IE00B2B36J28.USD","LU1035775433.USD","BK4534","IE00BJJMRX11.SGD","LU0079474960.USD","BK4585","LU1623119135.USD","LU0471298694.HKD","LU0320765059.SGD","LU0964807845.USD","LU0158827781.USD","LU0256863902.USD","LU2168564495.EUR","LU2237443978.SGD","LLY","LU0198837287.USD","LU2361044949.HKD","IE00BJJMRY28.SGD","LU0109394709.USD","LU0106261372.USD","LLII","LU0097036916.USD","BK4007","LU0320765992.SGD","SGXZ81514606.USD","LU1712237335.SGD","LU1280957306.USD","LU2211815571.USD","LU2552382132.HKD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU0354030511.USD","LU1988902786.USD","LU2087625088.SGD","LU0787776722.HKD","LU0943347566.SGD","GB00BDT5M118.USD","LU2168564222.USD","LU2750360997.AUD","BK4581","LU2552382058.USD","LU0882574055.USD","LU2357305700.SGD","IE0009355771.USD","LU1983299246.USD","LU2750360641.GBP","IE00B4R5TH58.HKD","LU2028103732.USD","LU2237443895.HKD","LU0820561909.HKD","LU2237443549.SGD","IE0001KFT4U8.USD","LU2756315664.SGD","LU1093756168.USD","LU1093756325.SGD","LU2237443465.HKD","LU1868837300.USD","LU2602419157.SGD","LU1127390331.HKD","LU2265009873.SGD","SGXZ99366536.SGD","LU0109391861.USD","LU2237443382.USD","BK4516","LU0354030438.USD","LU0432979614.USD","LU0061475181.USD","LU0289739699.SGD","SGXZ31699556.SGD","LU0234572021.USD","LU2089283258.USD","LU1145028129.USD","IE00BKPKM429.USD","IE0002141913.USD","IE00B4JS1V06.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643247738","title":"Legend Biotech announces first clinical proof-of-concept data for LB2501","url":"https://stock-news.laohu8.com/highlight/detail?id=2643247738","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643247738?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:50","pubTimestamp":1781470252,"startTime":"0","endTime":"0","summary":"Legend Biotech (LEGN) announced first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/legend-biotech-announces-first-clinical-proof-of-concept-data-for-lb2501-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/legend-biotech-announces-first-clinical-proof-of-concept-data-for-lb2501-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4230","BK4505","BK4022","CAR","BK4588","BK4139","BK4585","BK4581","LEGN","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643477312","title":"Oceania Healthcare Weighs 6-Year Secured Bond Offer for NZX Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643477312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643477312?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:48","pubTimestamp":1781470133,"startTime":"0","endTime":"0","summary":"Oceania Healthcare ( ($NZ:OCA) ) has provided an update. Oceania Healthcare is considering issuing 6-year fixed-rate, secured, unsubordinated bonds...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oceania-healthcare-weighs-6-year-secured-bond-offer-for-nzx-listing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oceania-healthcare-weighs-6-year-secured-bond-offer-for-nzx-listing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLTW","NZ50G.NZ","T10G.NZ","US30Y.BOND","NZT.NZ","US5Y.BOND","BK4581","TLT","US12M.BOND","XLV","XBI","FNZ.NZ","US6M.BOND","NZ20C.NZ","NZG.NZ","BK4588","TNZ.NZ","BK8050","LABU","US10Y.BOND","US7Y.BOND","BK4585","NZX.NZ","US2Y.BOND","BK8020","OCA.NZ","US3Y.BOND","TMF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643732247","title":"Ascendis Pharma completes Phase 3 PaTHway Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643732247","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643732247?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:40","pubTimestamp":1781469605,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH demonstr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-completes-phase-3-pathway-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ascendis-pharma-completes-phase-3-pathway-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","ASND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643247460","title":"Intellia Therapeutics presents additional results from Phase 3 HAELO trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2643247460","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643247460?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:35","pubTimestamp":1781469358,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics (NTLA) presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedem...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-presents-additional-results-from-phase-3-haelo-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/intellia-therapeutics-presents-additional-results-from-phase-3-haelo-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","NTLA","BK4139","LU1861558580.USD","BK4588","BK4585","BK4535","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643498247","title":"Rhythm announces preliminary data from Phase 2 trial of setmelanotide","url":"https://stock-news.laohu8.com/highlight/detail?id=2643498247","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643498247?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:35","pubTimestamp":1781469333,"startTime":"0","endTime":"0","summary":"Rhythm Pharmaceuticals (RYTM) announced preliminary data from a Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome deliv...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rhythm-announces-preliminary-data-from-phase-2-trial-of-setmelanotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rhythm-announces-preliminary-data-from-phase-2-trial-of-setmelanotide-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RYTM","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643247459","title":"Mirum, Incyte report pivotal Phase 2 PROGRESS data showing zilurgisertib cuts new FOP bone lesion volume 99.9% at Week 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2643247459","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643247459?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:35","pubTimestamp":1781469318,"startTime":"0","endTime":"0","summary":"Mirum Pharmaceuticals disclosed pivotal Phase 2 PROGRESS Cohort 1 results for oral ALK2 inhibitor zilurgisertib in FOP, already presented at ENDO 2026.The trial showed fewer new bone lesions and less overall disease progression on treatment versus placebo, with benefits sustained through 48 weeks.Patients who switched from placebo to zilurgisertib in the extension also showed no new lesions, supporting durability and crossover benefit.The FDA accepted an NDA for patients aged 12 and older with Priority Review, setting a PDUFA target action date of September 26, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on June 14, 20","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nNDL28XmZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","MIRM","INCY","BK4139","BK4588","BK4550","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643455247","title":"Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results From Progress Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva","url":"https://stock-news.laohu8.com/highlight/detail?id=2643455247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643455247?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:35","pubTimestamp":1781469300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nTUA8VC1DP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4550","INCY","BK4588","BK4532","BK4139","BK4585","MIRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643471082","title":"Crinetics says Phase 2 trial shows atumelnant cuts CAH androgen levels 67% while enabling glucocorticoid dose reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2643471082","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643471082?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:30","pubTimestamp":1781469018,"startTime":"0","endTime":"0","summary":"Crinetics presented full Phase 2 adult CAH results for once-daily atumelnant at ENDO 2026.Study showed sustained androgen suppression while allowing most participants to reduce steroid supplementation to physiologically normal levels.Separate ENDO 2026 presentation disclosed early Phase 1b/2a data in ACTH-dependent Cushing’s syndrome showing rapid cortisol lowering, with some normalization.Tolerability appeared manageable, with adverse events largely consistent with adrenal insufficiency and typically improved with replacement steroids.Program moved into late-stage development, with adult and pediatric Phase 3 trials already underway.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nNDL6MBVW5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRNX","SG9999014005.SGD","SG9999014021.USD","IE00BN0W2W23.USD","LU0314104364.USD","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210150020.SGD","IE00B64PRP62.GBP","BK4139","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643724746","title":"Belite Bio completes rolling submission of NDA to U.S. FDA for tinlarebant","url":"https://stock-news.laohu8.com/highlight/detail?id=2643724746","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643724746?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:30","pubTimestamp":1781469005,"startTime":"0","endTime":"0","summary":"Belite Bio (BLTE) announced the completion of its rolling submission of a New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/belite-bio-completes-rolling-submission-of-nda-to-u-s-fda-for-tinlarebant-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/belite-bio-completes-rolling-submission-of-nda-to-u-s-fda-for-tinlarebant-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","LABU","BK4585","BLTE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643240821","title":"Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643240821","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643240821?lang=en_us&edition=fundamental","pubTime":"2026-06-15 04:30","pubTimestamp":1781469000,"startTime":"0","endTime":"0","summary":"Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New resul","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/14/3311470/0/en/Crinetics-Presents-Full-Results-From-Phase-2-Trial-of-Atumelnant-in-Congenital-Adrenal-Hyperplasia-CAH-in-Oral-Presentation-at-ENDO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930227.SGD","LU0310799852.SGD","BK4588","LU0162691827.USD","LU1880398471.USD","LU0310800965.SGD","LU0006061336.USD","LU0072461881.USD","LU0154236417.USD","LU1880398554.USD","LU0052756011.USD","LU1571399168.USD","BK4183","LU1267930813.SGD","SG9999001440.SGD","BK4551","BK4175","BK4196","PTH","LU0211327993.USD","BK4585","BK4535","ENDO","LU0211328371.USD","LU1267930490.SGD","LU0889566641.SGD","LU1983299246.USD","LU0128525689.USD","CAH","GH","LU0792757196.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643247698","title":"‘It Makes Little Sense,’ Says Investor About Micron Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2643247698","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643247698?lang=en_us&edition=fundamental","pubTime":"2026-06-15 03:49","pubTimestamp":1781466579,"startTime":"0","endTime":"0","summary":"For decades, investing in memory stocks came with a simple rule: enjoy the boom while it lasts, because the bust eventually follows. Micron (NASDAQ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/it-makes-little-sense-says-investor-about-micron-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/it-makes-little-sense-says-investor-about-micron-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2750360997.AUD","LU2089985449.USD","IE00BK4W5M84.HKD","LU1323610961.USD","IE0002270589.USD","LU0157215616.USD","LU2471134879.HKD","LU2750360641.GBP","LU0081259029.USD","LU0683600562.USD","LU2054465674.USD","LU1852331112.SGD","LU2286300806.USD","BK4579","BK4554","BK4588","LU2211815571.USD","LU0203345920.USD","IE00B19Z3B42.SGD","LU0889566641.SGD","BK4566","LU0642271901.SGD","LU2360106780.USD","LU2458330169.SGD","MUU","BK4585","BK4141","LU0154236417.USD","LU2543165471.USD","BK4605","LU2931357623.SGD","LU2458330243.SGD","LU0127658192.USD","LU1267930813.SGD","BK4533","LU1366333091.USD","LU0109392836.USD","LU2357627491.SGD","IE0009356076.USD","LU0787776722.HKD","BK4553","LU0859254822.USD","MUD","LU2471134952.CNY","BK4543","LU2048586759.USD","LU2471134523.USD","SG9999001424.SGD","BK4512","BK4532","LU2250418816.HKD","IE00BK4W5L77.USD","BK4527","LU0719512351.SGD","MU","IE00B5949003.HKD","LU1316542783.SGD","MULL","LU0792757196.USD","LU1914381329.SGD","LU0082616367.USD","LU0056508442.USD","IE00B19Z3581.USD","LU0889565833.HKD","LU1803068979.SGD","LU0274383776.USD","LU0203347892.USD","BK4575","IE00B7SZLL34.SGD","GB00BDT5M118.USD","LU2471134796.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643724773","title":"How Investors Are Reacting To China Medical System (SEHK:867) Advancing Its siRNA-Based Obesity Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2643724773","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643724773?lang=en_us&edition=fundamental","pubTime":"2026-06-15 03:18","pubTimestamp":1781464694,"startTime":"0","endTime":"0","summary":"China Medical System Holdings recently reported at the American Diabetes Association’s 86th Scientific Sessions that its self-developed siRNA candidate CMS-D008 achieved significant fat-specific weight loss with preserved muscle mass and a favorable safety profile in obese animal models, while its Phase I trial in healthy subjects continues to progress.\nThe company also highlighted how CMS-D008 may work in combination with its GLP-1R/GCGR dual agonist CMS-D005, underscoring an emerging,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/how-investors-are-reacting-to-china-medical-system-sehk867-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/how-investors-are-reacting-to-china-medical-system-sehk867-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1593","BK4211","BK1191","BK4587","IE00BYV24P56.USD","LU2488822045.USD","CHAT","BK4528","BK4588","AGIX","SG9999015978.USD","AIPO","IE00BMCWC346.EUR","SG9999015952.SGD","ARTY","SG9999004220.SGD","AIYY","BK4543","IE00BVYPNP33.GBP","00867","AI","ISBC","SG9999015986.USD","IE00BVYPNQ40.USD","IE00BGHQDM52.EUR","BK4551","BK4585","SG9999015945.SGD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643247221","title":"Does Cathay Pacific (SEHK:293) CFO Succession Hint At A Shift In Financial Strategy Priorities?","url":"https://stock-news.laohu8.com/highlight/detail?id=2643247221","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643247221?lang=en_us&edition=fundamental","pubTime":"2026-06-15 03:15","pubTimestamp":1781464548,"startTime":"0","endTime":"0","summary":"Cathay Pacific Airways has announced that Chief Financial Officer and Executive Director Rebecca Jane Sharpe will retire from the Swire group on 1 October 2026, to be succeeded by Gavin John March, currently finance director at Swire Bulk Holdings.\nThe planned handover to March, who brings aviation, engineering and shipping finance experience from across the Swire group, reshapes the airline’s senior financial leadership profile.\nWe’ll now examine how this planned CFO transition to Gavin...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3221000-choice1-main-header/1585186659178","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3221000-choice1-main-header/1585186659178"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/transportation/hkg-293/cathay-pacific-airways-shares/news/does-cathay-pacific-sehk293-cfo-succession-hint-at-a-shift-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/transportation/hkg-293/cathay-pacific-airways-shares/news/does-cathay-pacific-sehk293-cfo-succession-hint-at-a-shift-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","CHAT","AI","BK1561","BK4585","00293","AGIX","BK4023","BK4528","AIPO","BK1123","BK4543","BK4551","BK4587","ARTY","AIYY"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1151,"pageCount":1,"totalSize":23001,"code":"91000000","status":"200"}]}}